Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Agostinetto

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Cancers|May 14, 2022
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future PerspectivesElisa Agostinetto, Filippo Montemurro, Fabio Puglisi, et al.
The Lancet. Oncology|April 23, 2021
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancerMaria Alice Franzoi, Elisa Agostinetto, Marta Perachino, et al.
International Journal of Cancer|June 22, 2022
Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditisRiccardo Cau, Cinzia Solinas, Pushpamali De Silva, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2023
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysisFlavia Jacobs, Chiara Molinelli, Diogo Martins-Branco, et al.
Oncology|July 24, 2018
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Elisa Agostinetto, Giovanna Masci, et al.
Breast (Edinburgh, Scotland)|March 29, 2021
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumabRita De Sanctis, Laura Giordano, Federica D'Antonio, et al.
Clinical Breast Cancer|March 21, 2024
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA TrialVeronique Debien, Elisa Agostinetto, Marco Bruzzone, et al.
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
Scientific Reports|November 19, 2020
Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practiceAgnese Losurdo, Rita De Sanctis, Bethania Fernandes, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Cancers|May 14, 2022
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future PerspectivesElisa Agostinetto, Filippo Montemurro, Fabio Puglisi, et al.
The Lancet. Oncology|April 23, 2021
Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancerMaria Alice Franzoi, Elisa Agostinetto, Marta Perachino, et al.
International Journal of Cancer|June 22, 2022
Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditisRiccardo Cau, Cinzia Solinas, Pushpamali De Silva, et al.
Cancers|November 11, 2022
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast CancerElisa Agostinetto, Flavia Jacobs, Véronique Debien, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2023
Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysisFlavia Jacobs, Chiara Molinelli, Diogo Martins-Branco, et al.
Oncology|July 24, 2018
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer PatientsRita De Sanctis, Elisa Agostinetto, Giovanna Masci, et al.
Breast (Edinburgh, Scotland)|March 29, 2021
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumabRita De Sanctis, Laura Giordano, Federica D'Antonio, et al.
Clinical Breast Cancer|March 21, 2024
The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA TrialVeronique Debien, Elisa Agostinetto, Marco Bruzzone, et al.
Expert Opinion on Investigational Drugs|March 4, 2022
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancerElisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, et al.
Scientific Reports|November 19, 2020
Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practiceAgnese Losurdo, Rita De Sanctis, Bethania Fernandes, et al.
Pageof 8